Filing Details
Protalix BioTherapeutics, Inc. (AMEX:PLX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedAMEX:PLX
Protalix BioTherapeutics, Inc. (PLX) Files Quarterly Report for Q0
Protalix BioTherapeutics, Inc. (AMEX:PLX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
Protalix BioTherapeutics, Inc. (AMEX:PLX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Protalix BioTherapeutics filed its Q0 2026 quarterly report (Form 10-Q) on August 12, 2026, though the specific revenue figure is not disclosed in this summary.
- The company's stock trades at $2.62 per share with a market capitalization of $146.4 million as of the filing date.
- The 10-Q filing includes unaudited financial statements and management commentary on business performance, though the article does not provide details on financial results or material changes in business conditions.
Market Context
Protalix BioTherapeutics, Inc.'s stock currently trades at $2.62 with a market capitalization of $146.4M.
The 10-Q provides Protalix BioTherapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Protalix BioTherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PLX Stock Page
Frequently Asked Questions
Where can I read PLX's SEC filings?
Browse all filings on our PLX SEC filings page.
What types of SEC filings does Protalix BioTherapeutics, Inc. file?
Public companies like Protalix BioTherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.